13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001727492
Total reported value
$2.1B
$2.1B
16 檔
15.7%
As reported in its official Q1 2025 Form 13F filing, Caligan Partners LP's tracked investment portfolio stood at $2.1B with 16 total positions.
In Q1 2025, Caligan Partners LP displayed an active expansion posture, initiating 3 new positions and adding to 8 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LQDA | Liquidia CORP | Stock-Other | 24.99% | +10.06% | — | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 19.04% | — | — | |
| 3 | EXEL | Exelixis Inc | Stock-Healthcare | 11.75% | -0.45% | — | |
| 4 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 7.12% | -5.00% | EXIT | |
| 5 | EOLS | Evolus Inc | Stock-Other | 6.86% | — | +1.44% | |
| 6 | SG7 | Sage Therapeutics Inc | Stock-Other | 5.06% | — | — | |
| 7 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 4.86% | — | +3.73% | |
| 8 | ANIK | Anika Therapeutics Inc | Stock-Other | 4.50% | -0.39% | — | |
| 9 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 4.29% | -0.04% | +11.98% | |
| 10 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.43% | +7.32% | — | |
| 11 | ✓ | Merus N V | Stock-Other | 3.31% | — | +47.83% | |
| 12 | YMABUSD | Y-mabs Therapeutics Inc | Stock-Other | 2.17% | — | +32.50% | |
| 13 | ABVX | Abivax Sa-adr | Stock-Other | 1.66% | -1.06% | +68.73% | |
| 14 | ✓ | Verrica Pharmaceuticals Inc | Stock-Other | 0.83% | — | +21.04% | |
| 15 | RZLT | Rezolute Inc | Stock-Other | 0.09% | — | — | |
| 16 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.05% | -2.04% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MLYS | Mineralys Therapeutics Inc | +4% | +112.60% | Add |
| 2 | RVMD | Revolution Medicines Inc | +3.4% | NEW | New buy |
| 3 | VRNA | Verona Pharma PLC - Adr | +2.1% | — | Unchanged |
| 4 | SG7 | Sage Therapeutics Inc | +0.9% | — | Unchanged |
| 5 | ✓ | Merus N V | +0.6% | +47.83% | Add |
| 6 | ABVX | Abivax Sa-adr | +0.3% | +68.73% | Add |
| 7 | RZLT | Rezolute Inc | +0.1% | NEW | New buy |
| 8 | TYRA | Tyra Biosciences Inc | +0.1% | NEW | New buy |
| 9 | ENTA | Enanta Pharmaceuticals Inc | -0.3% | EXIT | Sold out |
| 10 | ✓ | Verrica Pharmaceuticals Inc | -0.5% | +21.04% | Add |
| 11 | EOLS | Evolus Inc | -0.7% | +1.44% | Add |
| 12 | BCRX | Biocryst Pharmaceuticals Inc | -0.9% | +3.73% | Add |
| 13 | AGIO | Agios Pharmaceuticals Inc | -0.9% | +11.98% | Add |
| 14 | EXEL | Exelixis Inc | -1.1% | — | Unchanged |
| 15 | YMABUSD | Y-mabs Therapeutics Inc | -1.3% | +32.50% | Add |
| 16 | ANIK | Anika Therapeutics Inc | -1.5% | — | Unchanged |
| 17 | LQDA | Liquidia CORP | -4.3% | — | Unchanged |
According to official SEC Form 13F filings, Caligan Partners LP reported a total U.S. public equity portfolio value of $2.1B across 16 disclosed positions in Q1 2025.
During Q1 2025, Caligan Partners LP's top holdings by market value included LQDA (25.0%)、VRNA (19.0%)、EXEL (11.8%). The largest single position, LQDA, represented 25.0% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LQDA, VRNA, EXEL) accounted for 15.7% of total reported equity market value during Q1 2025.
Top New Position Initiated
RVMD
市值: $16.4M
Top Position Liquidated / Trimmed
ENTA
前期市值: $1.1M
In Q1 2025, Caligan Partners LP made 12 total portfolio adjustments, initiating 3 new buys, adding to 8 positions, trimming 0 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.